Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

ImmVira Completes C Round for Oncolytic Virus and Vector Candidates

publication date: Dec 31, 2020

Shenzhen ImmVira completed a Series C financing of undisclosed size. The company focuses on the use of oncolytic viruses and vector approaches for cancer drugs that promise increased safety and efficacy over other types of drug delivery. The company will use the proceeds to fund an international multi-center trial for its lead product (MVR-T3011-IT) plus filing INDs and starting clinical trials for two additional pipeline candidates. In August, ImmVira out-licensed Greater China rights for MVR-T3011 to Shanghai Pharma in an agreement worth up to $176 million. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital